Abstract
A few studies examined the comparative side effects of Coronavirus Disease-19 (COVID-19) vaccines. We compared the extension and severity of self-reported side effects of seven COVID-19 vaccines [BNT162b2 (Pfizer-BioNTech), ChAdOx1 (AstraZeneca), mRNA-1273 (Moderna), CoronaVac (Sinovac Life Sciences), Gam-COVID-Vac (Gamaleya's Sputnik V), Ad5-nCoV (CanSinoBIO), and Ad26.CoV2.S (Johnson & Johnson/Janssen)] in the Mexican population. We also evaluated the association of type of vaccine, sex, age, comorbidity, and history of allergies to the extent and severity of side effects. This was a cross-sectional study carried out online between August 12 and September 3, 2021 in Mexico. The first inclusion criterion was to receive a COVID-19 vaccine and the second, being at least 18 years old. The survey link was distributed via multiple social media platforms. We questioned about the type of vaccine and symptoms based on short-term side effects reported in the literature. Side effect extension was classified as local, systemic, or both. We asked about the need to take medicine, stop activities/miss work, or seek medical attention. Then, a severity index was constructed based on responses. Descriptive and stepwise multivariate logistic ordinal regression analyses were used to calculate odds ratio (OR) and 95% CI for each outcome adjusted by potential confounders. The mean age was 38.9 ± 11.0 years (n = 4,024). Prevalence of at least one side effect varied between vaccines and by a number of doses. At dose 1, ChAdOx1 was the vaccine with the highest rate of at least one side effect (85%) followed by Gam-COVID-Vac (80%). Both were associated to greater extension (adjusted OR 2.53, 95% CI 2.16, 2.96 and adjusted OR 2.41, 95% CI 1.76, 3.29, respectively) and severity of side effects (adjusted OR 4.32, 95% CI 3.73, 5.00 and adjusted OR 3.00, 95% CI 2.28, 3.94, respectively). Young age (<50 years), female sex, comorbidity, and history of allergies were associated with greater extension and severity, independent of the type of vaccine and potential confounders. At dose 2, mRNA-1273 was the vaccine with the highest rate of side effects (88%) and the only vaccine associated to greater extension (adjusted OR 2.88, 95% CI 1.59, 5.21) and severity of symptoms (adjusted OR 3.14, 95% CI 1.82, 5.43). Continuous studies are necessary to acknowledge more post-vaccine symptoms in different populations.
Introduction
By January 2020, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that originated in Wuhan, China had already spread to Europe and by March 2020, it had already spread to the whole world (1–4). The number of people infected was rapidly reached stunning figures given its high transmissibility. The health services collapsed, and the loss of life was alarming in the absence of a specific treatment. Fortunately, Coronavirus Disease-19 (COVID-19) vaccines emerged in record time. Clinical trials began to show the efficacy and safety of vaccines, such as the mRNA-1273 vaccine (Moderna) (5), the BNT162b2 vaccine (Pfizer-BioNTech), and the Gam-COVID-Vac (Gamaleya's Sputnik V) (6). Therefore, regulatory agencies began authorizing their emergency use. Starting date and requirements for the public to receive the vaccine varied by region. In Mexico, vaccination started in December 2020 and the administration was in stages according to priority groups with vaccines varying in type upon availability (Figure 1) (7). Additionally, some Mexicans sought to receive a vaccine abroad, mainly the United States, where mRNA-1273 (Moderna), Ad26.CoV2.S (Johnson & Johnson/Janssen), and BNT162b2 (Pfizer-BioNTech) were available. Vaccine acceptability is key to the success of any vaccination program. Two nationally representative surveys on COVID-19 vaccination are available in Mexico. One, conducted from August to November 2020, identified 62.3% acceptance, 28.2% refusal, and 9.5% hesitancy (8). The second, conducted in November 2020, reported 82% acceptance. Although unlike the first, this study combined a doubtful answer with a definitive one (9). Reports on the progress of coverage of the vaccination strategy in the country showed 20% of the target population fully vaccinated by August 2021 (beginning of the data collection of the present study), and 59% by the end of January 2022 (10, 11).
Figure 1
Despite having proven their safety, COVID-19 vaccines are not exempt from adverse effects. Adverse reactions have been reported in more than 1 in 10 people in BNT162b2 (Pfizer-BioNTech), ChAdOx1 (AstraZeneca), and mRNA-1273 vaccine (Moderna) clinical trials. They usually happen shortly after the vaccination and are not associated with a serious or lasting illness (12–17). Moreover, some factors, such as young age, female sex, and prior COVID-19 infection, may increase the frequency of side effects (18–24). Pharmacovigilance activities are essential in any country. In Mexico, a web page is available for registration of vaccines' adverse effects directly by the public (25). However, there is no promotion of its use and much of the general population is unaware of its existence. Post-vaccination surveillance studies are needed worldwide because it is important to understand the frequency and regional variation of side effects and its potential impact on daily life, so that the public can successfully anticipate appropriate actions. A few studies examined the comparative side effects of COVID-19 vaccines (18, 21, 26) and the reactogenicity of more than three different types of vaccines has not been assessed on the same survey.
The objective of the present study was to compare the extension and severity of self-reported side effects of seven COVID-19 vaccines [BNT162b2 (Pfizer-BioNTech), ChAdOx1 (AstraZeneca), mRNA-1273 (Moderna), CoronaVac (Sinovac Life Sciences), Gam-COVID-Vac (Gamaleya's Sputnik V), Ad5-nCoV (CanSinoBIO), and Ad26.CoV2.S (Johnson & Johnson/Janssen)] in the Mexican population. A second objective was to evaluate the association of type of vaccine, sex, age, comorbidity, and history of allergies to the extent and severity of side effects.
Materials and Methods
Study Design
This was a cross-sectional study carried out online between August 12 and September 3, 2021 in Mexico (two months after the vaccination was opened to all population groups). Nuevo Leon and Mexico City were the locations with more participants (Figure 2). The first inclusion criterion was to receive a COVID-19 vaccine and the second, being at least 18 years old. Those who did not sign the informed consent were excluded and there was no need to eliminate any registry due to lack of information on vaccine adverse effects. Non-random sampling based on the snowballing technique was used for recruiting potential participants who were invited through social media groups and word-of-mouth campaigns with no proportional quotas by sociodemographic variables or by type of vaccine. The survey link was distributed via multiple media platforms, such as Facebook and WhatsApp. Participants did not receive any kind of financial reward. Two sample sizes were estimated. One is based on the expected frequency of at least one local side effect between 48.9 and 85.8% reported in the literature (22, 27). The second is based on the expected frequency of at least one systemic side effect between 52.6 and 70.5% (22, 27). Both, with a margin of error of 3% and a CI of 95%. The minimum n required varied from 514 to 1,067 for estimates of local effects and between 879 and 1,064 for estimates of systemic effects. However, there were 4,024 participants. Such a sample size provided determinations with a precision of <2% and confidence level >95% given the frequencies obtained in the study of 67 and 65% for local and systemic side effects after the 1st dose (28). The protocol was approved by the Committees of Ethics and Health Research (R2021-1909-106). The study followed the Declaration of Helsinki for research on human subjects' guidelines (29). All the participants had to give their informed consent digitally before filling in the questionnaire. Participation was entirely voluntary, and withdrawal was allowed at any time without the need to justify the decision. There was no personal data collected that might enable the retrospective identification of the participant.
Figure 2
Study Variables
Vaccine Information
Participants were asked about the type of vaccine received (multiple choice), vaccine combination (yes, no; if yes, type of combination), and the number of doses. Moreover, about the use of pre-vaccination medication to prevent symptoms (yes, no). For side effects evaluation, the participant chose all the symptoms that he/she had presented from a list made with short-term side effects reported in the literature (12–17). Then, the extension was classified as local, systemic, or both. To simplify the questionnaire as much as possible, the time of onset and duration for each side effect were not included. The side effects of dose 1 and dose 2 were questioned in separate sections. For severity evaluation, three questions were asked for first or single dose: need to take medicine, stop activities/miss work, or seek medical attention (went to a doctor, went to an emergency room, or was hospitalized). Then, an index was constructed based on negative and affirmative responses obtaining 3 categories: mild, moderate, and severe (Table 1). One question was used for the second dose: notice any difference in symptomatology between the first and second doses (felt better, felt the same, or felt worse).
Table 1
| Severity | Took medicine to relieve symptom | Suspended daily activity or missed work | Sought medical attention |
|---|---|---|---|
| Mild | Yes | No | No |
| Moderate | Yes | Yes | No |
| Severe | Yes or No | Yes or No | Yes, regardless of the need to take medication or suspend activities/miss work |
Severity categorization.
Study on self-reported side effects of Coronavirus Disease-19 (COVID-19) vaccines in the Mexican population, August to September 2021.
Comorbidity, Sociodemographic, and Other Characteristics
One question filtered the history of any comorbidity. Those who answered affirmatively were asked about a previous diagnosis of prediabetes, diabetes, hypertension, chronic renal failure, chronic obstructive lung disease, asthma, immune disease, cancer, cerebrovascular disease, others. Moreover, about the history of allergies and COVID-19 infection (had symptoms consistent with COVID-19 disease and was positive to PCR or rapid nasal swab antigen test). Sex, age, schooling, occupation, place of residence, smoking, pregnancy, and breastfeeding at the time of vaccination were identified too. Nutritional status was assessed using a validated body mass index-body size pictorial method that indicated low weight (shape 1), normal weight (shapes 2 and 3), overweight (shape 4), and obesity (shapes 5–10) (30).
Study Procedures
The self-applied electronic survey was designed in Spanish with the software tool QuestionPro (Survey Analytics LLC, San Francisco, CA, USA) and Google Forms (Google, Mountain View, CA, USA). The survey took an average of 5 min to complete. It was divided into the following sections: privacy policy (statements about voluntary participation and confidentiality), vaccine data, post-vaccination side effects, COVID-19 prior infection, and comorbidity data; sociodemographic and other information of interest. The items were developed by the authors after a thorough review of the literature on side effects reported by the different vaccines. These were submitted to a panel of experts (an epidemiologist medical doctor and 2 full-time medical researchers) who reviewed the pertinence and relevance of the content. Moreover, they checked if writing was clear, concise, and unambiguous and verified the absence of technical language. The proposed questionnaire was pre-tested among colleagues, then it was tested in a pilot study with participants of sociodemographic characteristics similar to the target population. Some adjustments were made on section skipping according to filter questions. The final version is available in Supplementary Materials S1.
Statistical Analysis
Frequencies were obtained for the categorical variables, as were means and SDs for the non-categorical variables. Point prevalence and 95% CIs were estimated. The association of sociodemographic, comorbidity, and history of allergies to extension and severity of side effects was evaluated through the chi-square tests. Then, stepwise multivariate logistic ordinal regression models were run to calculate adjusted odds ratio (OR) and 95% CI for each outcome of interest. One model included an extension of side effects as dependent variable (coded as absent, local, systemic, both) and type of vaccine, sex, age, comorbidity, allergies, and smoking as independent variables; use of pre-vaccination medication to prevent symptoms and history of confirmed COVID-19 infection were used as control variables. The model for analyzing severity included severity index (coded as absent, mild, moderate, and severe) or difference in symptomatology between first and second doses (coded as felt better, felt the same, or felt worse) as dependent variables. Outcomes were analyzed for dose 1 and dose 2, separately. Due to the small sample size, 4 records were removed from inferential statistical analysis, 1 BBIBP-CorV (Sinopharm, Beijing, China) registry, and 3 CureVac registries. Analyses were done using SPSS for Windows version 22.
Results
The mean age was 38.9 ± 11.0 years, 3.6% were pregnant and 9.9% were breastfeeding when they got the vaccine. The female sex, the bachelor's school degree, and being employed or self-employed were characteristics that predominated in the study population. Some characteristics differed by type of vaccine. There were more participants between 30 and 39 years with ChAdOx1 (AstraZeneca), Gam-COVID-Vac (Gamaleya's Sputnik V), Ad5-nCoV (CanSinoBIO), and Ad26.CoV2.S (Johnson & Johnson/Janssen). Moreover, more participants with higher schooling and employed/self-employed with Ad5-nCoV (CanSinoBIO). Table 2 shows these and other detailed results. A very low percentage of combined vaccines (2%) and 67.4% had a complete scheme (two doses or one for single-shot vaccines). Less than 7% of participants used medication to prevent symptoms before the first or second vaccinations (6.9 and 6.5%, respectively, p = 0.549).
Table 2
| Type of vaccine | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total | Pfizera | AstraZenecab | Modernac | SinoVacd | Sputnik Ve | Cansinof | J & Jg | Chi-square p-value | |
| n = 4,024 | n =1,579 | n =1,193 | n =52 | n =299 | n =202 | n =598 | n =97 | ||
| Female | 79.7% | 79.4% | 79.3% | 76.9% | 78.9% | 84.2% | 80.4% | 79.4% | 0.778 |
| Age group (years) | |||||||||
| <29 | 18.8% | 16.2% | 19.5% | 21.2% | 27.2% | 24.8% | 17.1% | 23.7% | |
| 30–39 | 41.9% | 36.7% | 47.8% | 28.8% | 30.9% | 49.0% | 46.9% | 50.5% | |
| 40–49 | 21.2% | 24.0% | 20.1% | 30.8% | 16.8% | 1.0% | 25.6% | 12.4% | |
| 50 a 59 | 12.3% | 16.3% | 6.2% | 11.5% | 13.8% | 19.8% | 10.2% | 13.4% | |
| ≥60 | 5.8% | 6.8% | 6.4% | 7.7% | 11.4% | 5.4% | 0.2% | 0.0% | 0.0001 |
| Schooling | |||||||||
| Middle school | 3.0% | 3.3% | 4.0% | 0.0% | 5.0% | 1.5% | 0.3% | 2.1% | |
| High school | 11.3% | 11.4% | 14.9% | 3.8% | 19.1% | 9.4% | 2.2% | 6.2% | |
| Bachelor's degree | 50.1% | 48.7% | 52.1% | 53.8% | 53.5% | 54.0% | 44.8% | 61.9% | |
| Postgraduate | 35.5% | 36.6% | 28.9% | 42.3% | 22.4% | 35.1% | 52.7% | 29.9% | 0.0001 |
| Occupation | |||||||||
| Employed/self-employed | 71.6% | 75.0% | 63.5% | 75.0% | 59.2% | 57.9% | 90.1% | 66.0% | |
| Housewife | 12.1% | 11.0% | 16.2% | 17.3% | 15.7% | 14.4% | 1.7% | 23.7% | |
| Retired/unemployed | 7.7% | 7.7% | 9.3% | 1.9% | 11.4% | 13.4% | 2.3% | 1.0% | |
| Student | 8.6% | 6.2% | 11.1% | 5.8% | 13.7% | 14.4% | 5.9% | 9.3% | 0.0001 |
| Smoking | 13.1% | 13.5% | 14.6% | 15.4% | 13.7% | 8.9% | 10.5% | 8.2% | 0.075 |
| Comorbidity (any) | 19.3% | 22.9% | 16.3% | 15.4% | 18.4% | 18.3% | 18.9% | 7.2% | 0.0001 |
| Hypertension | 7.4% | 9.4% | 6.4% | 9.6% | 7.0% | 6.4% | 5.7% | 2.1% | 0.006 |
| Prediabetes or diabetes | 4.8% | 6.2% | 4.1% | 1.9% | 4.0% | 3.0% | 4.2% | 1.0% | 0.025 |
| Allergies | 30.9% | 30.8% | 30.9% | 32.7% | 28.4% | 23.3% | 34.8% | 27.8% | 0.085 |
| COVID-19 before 1st dose | 17.4% | 22.0% | 15.6% | 17.3% | 17.4% | 11.9% | 12.4% | 7.2% | 0.0001 |
| Overweight/obese | 54.7% | 56.3% | 53.5% | 51.9% | 54.8% | 44.1% | 57.9% | 46.4% | 0.010 |
Sociodemographic, comorbidity, and other characteristics.
Study on self-reported side effects of Coronavirus Disease-19 (COVID-19) vaccines in the Mexican population, August to September 2021 (n = 4,024).
BNT162b2 (Pfizer-BioNTech).
ChAdOx1 (AstraZeneca).
mRNA-1273 (Moderna).
CoronaVac (Sinovac Life Sciences).
Gam-COVID-Vac (Gamaleya's Sputnik V).
Ad5-nCoV (CanSinoBIO).
Ad26.CoV2.S (Johnson & Johnson/Janssen).
Extension of Side Effects
Prevalence of side effects varied by type of vaccines and number of doses. ChAdOx1 (AstraZeneca) was the vaccine with the highest prevalence of at least one side effect at dose 1 and mRNA-1273 (Moderna), at dose 2 (Figure 3). Stratification by local and systemic effects showed the prevalence of 67% (95% CI 65.1, 68.0) and 65% (95% CI 63.3, 66.2) after the first vaccination, respectively. The classification by extension showed that the combination of local and systemic effects was the most frequent category after the first dose, which exceeded that of the second dose. Arm/injection site pain was the most common local symptom and headache was the most common systemic symptom regardless of the number of doses (Table 3). Side effects categorized by organ system and the number of doses are provided in Supplementary Table S2. Side effects categorized by organ system and type of vaccine are provided in Supplementary Tables S3, S4.
Figure 3
Table 3
| First or single dose vaccination (n= 4,024) | Second dose vaccination (n= 2,050) | |||
|---|---|---|---|---|
| n | % (95% Confidence interval) | n | % (95% Confidence interval) | |
| Extension | ||||
| No symptoms | 975 | 24.2 (22.9, 25.6) | 778 | 38.0 (35.9, 40.1) |
| Local symptoms | 443 | 11.0 (10.1, 12.0) | 274 | 13.4 (12.0, 14.9) |
| Systemic symptoms | 370 | 9.2 (8.3, 10.1) | 203 | 9.9 (8.7, 11.3) |
| Both, local and systemic symptoms | 2,236 | 55.6 (54.0, 57.1) | 795 | 38.8 (36.7, 40.9) |
| Type of local side effecta | ||||
| Arm /injection site pain | 2,650 | 65.9 (64.4, 67.3) | 1,061 | 51.8 (49.6, 53.9) |
| Injection site swelling | 334 | 8.3 (7.5, 9.2) | 103 | 5.0 (4.2, 6.1) |
| Injection site itching | 210 | 5.2 (4.6, 5.9) | 54 | 2.6 (2.0, 3.4) |
| Injection site redness | 168 | 4.2 (3.6, 4.8) | 50 | 2.4 (1.9, 3.2) |
| Type of systemic side effecta | ||||
| Headache | 1,537 | 38.2 (36.7, 39.7) | 541 | 26.4 (24.5, 28.3) |
| Muscle pain | 1,293 | 32.1 (30.7, 33.6) | 370 | 18.0 (16.4, 19.8) |
| Lack of energy | 1,115 | 27.7 (26.3, 29.1) | 312 | 15.2 (13.7, 16.8) |
| Fatigue or tiredness | 1,107 | 27.5 (26.2, 28.9) | 477 | 23.3 (21.5, 25.1) |
| Fever | 926 | 23.0 (21.7, 24.3) | 236 | 11.5 (10.2, 13.0) |
| Desire to sleep | 912 | 22.7 (21.4, 24.0) | 300 | 14.6 (13.2, 16.2) |
| Chills | 817 | 20.3 (19.1, 21.6) | 214 | 10.4 (9.2, 11.8) |
| Malaise | 760 | 18.9 (17.7, 20.1) | 259 | 12.6 (11.3, 14.1) |
| Bone or joint pain | 713 | 17.7 (16.6, 18.9) | 222 | 10.8 (9.6, 12.2) |
| Nausea | 274 | 6.8 (6.1, 7.6) | 69 | 3.4 (2.7, 4.2) |
| Dizziness and giddiness | 265 | 6.6 (5.9, 7.4) | 76 | 3.7 (3.0, 4.6) |
| Hot flashes | 255 | 6.3 (5.6, 7.1) | 60 | 2.9 (2.3, 3.7) |
| Eye movement pain | 253 | 6.3 (5.6, 7.1) | 55 | 2.7 (2.1, 3.5) |
| Sweating | 236 | 5.9 (5.2, 6.6) | 55 | 2.7 (2.1, 3.5) |
| Stuffy nose | 197 | 4.9 (4.3, 5.6) | 61 | 3 (2.3, 3.8) |
| Sore throat | 191 | 4.7 (4.1, 5.4) | 72 | 3.5 (2.8, 4.4) |
| Diarrhea | 177 | 4.4 (3.8, 5.1) | 71 | 3.5 (2.8, 4.3) |
| Chest pain | 174 | 4.3 (3.7, 5.0) | 45 | 2.2 (1.6, 2.9) |
| A faster or lower heartbeat | 166 | 4.1 (3.6, 4.8) | 41 | 2.0 (1.5, 2.7) |
| Irritated eyes | 130 | 3.2 (2.7, 3.8) | 31 | 1.5 (1.1, 2.1) |
| Running nose | 124 | 3.1 (2.6, 3.7) | 54 | 2.6 (2, 3.4) |
| Difficulty breathing (dyspnea) | 107 | 2.7 (2.2, 3.2) | 25 | 1.2 (0.8, 1.8) |
| Abdominal pain | 96 | 2.4 (2.0, 2.9) | 25 | 1.2 (0.8, 1.8) |
| Lymph nodes tenderness | 91 | 2.3 (1.8, 2.8) | 38 | 1.9 (1.4, 2.5) |
| Cough | 90 | 2.2 (1.8, 2.7) | 34 | 1.7 (1.2, 2.3) |
| Rise in blood pressure | 87 | 2.2 (1.8, 2.7) | 15 | 0.7 (0.4, 1.2) |
| Vomiting | 57 | 1.4 (1.1, 1.8) | 20 | 1.0 (0.6, 1.5) |
| Skin rash, hives, irritable skin | 50 | 1.2 (0.9, 1.6) | 11 | 0.5 (0.3, 1.0) |
| Loss of blood pressure | 44 | 1.1 (0.8, 1.5) | 7 | 0.3 (0.2, 0.7) |
| Other | 92 | 2.3 (1.9, 2.8) | 23 | 1.1 (0.7, 1.7) |
Extension of side effects by the number of doses.
Study on self-reported side effects of Coronavirus Disease-19 (COVID-19) vaccines in the Mexican population, August to September 2021.
Ordered from highest to lowest frequency after first dose.
Severity of Side Effects
After dose 1, 62.6% needed to take medicine for relieving symptoms, 31.3% suspended daily activities or missed work, and 5.3% sought medical attention. The severity index showed 28% had mild, 21% moderate, and 4% severe effects; the rest did not experience symptoms, did not take medication, stopped activities, or sought medical attention (47%). The severity of side effects differed by type of vaccine. At dose 1, there were more respondents suspending activities/missing work and taking medicine for relieving symptoms with ChAdOx1 (AstraZeneca) and more seeking medical attention with Ad5-nCoV (CanSinoBIO) (Table 4).
Table 4
| Type of vaccine | ||||||||
|---|---|---|---|---|---|---|---|---|
| Pfizera | AstraZenecab | Modernac | SinoVacd | Sputnik Ve | Cansinof | J & Jg | Chi-square p-value | |
| Dose 1 | ||||||||
| Suspended daily activities/missed work | 164 (14.2%) | 498 (49.2%) | 5 (13.9%) | 39 (23.8%) | 63 (39.1%) | 168 (37.7%) | 16 (23.2%) | 0.0001 |
| Sought medical attention | 42 (3.6%) | 67 (6.6%) | 1 (2.8%) | 8 (4.9%) | 5 (3.1%) | 37 (8.3%) | (1) 1.4% | 0.001 |
| Took medicine | 598 (51.7%) | 804 (79.4%) | 27 (75%) | 69 (42.1%) | 105 (65.2%) | 252 (56.4%) | 52 (75.4%) | 0.0001 |
| Severity index | ||||||||
| None | 935 (59.2%) | 312 (26.2%) | 24 (46.2%) | 212 (70.9%) | 75 (37.1%) | 289 (48.3%) | 43 (44.3%) | |
| Mild | 462 (29.3%) | 369 (30.9%) | 22 (42.3%) | 46 (15.4%) | 60 (29.7%) | 128 (21.4%) | 37 (38.1%) | |
| Moderate or severe | 182 (11.5%) | 512 (42.9%) | 6 (11.5%) | 41 (13.7%) | 67 (33.2%) | 181 (30.3%) | 17 (17.5%) | 0.0001 |
| Dose 2 | ||||||||
| Felt better | 434 (31.5%) | 190 (56.2%) | 5 (10%) | 41 (23.2%) | 31 (43.7%) | – | – | |
| Felt the same | 561 (40.7%) | 107 (31.7%) | 18 (36%) | 105 (59.3%) | 25 (35.2%) | – | – | |
| Felt worse | 383 (27.8%) | 41 (12.1%) | 27 (54%) | 31 (17.5%) | 15 (21.1%) | – | – | 0.0001 |
The severity of side effects by the number of dose and type of vaccine.
Study on self-reported side effects of Coronavirus Disease-19 (COVID-19) vaccines in the Mexican population, August to September 2021.
BNT162b2 (Pfizer-BioNTech).
ChAdOx1 (AstraZeneca).
mRNA-1273 (Moderna).
CoronaVac (Sinovac Life Sciences).
Gam-COVID-Vac (Gamaleya's Sputnik V).
Ad5-nCoV (CanSinoBIO).
Ad26.CoV2.S (Johnson & Johnson/Janssen).
Factors Associated to Extension of Side Effects
At dose 1, participants with ChAdOx1 (AstraZeneca) and Gam-COVID-Vac (Gamaleya's Sputnik V) were more likely to have local and systemic side effects than BNT162b2 (Pfizer-BioNTech). In contrast, participants with CoronaVac (Sinovac Life Sciences) were less likely to have such an outcome. At dose 2, mRNA-1273 (Moderna) increased the odds of greater side effects extension, while ChAdOx1 (AstraZeneca) and CoronaVac (Sinovac Life Sciences) decreased them. Factors, such as female sex, age under 50, and history of allergies, increased the possibilities of greater extension at doses 1 and 2, regardless of comorbidity, smoking, pre-vaccination medication to prevent symptoms, and history of confirmed COVID-19 infection (Table 5).
Table 5
| Extension | ||||||
|---|---|---|---|---|---|---|
| Absent | Local | Systemic | Local and systemic | Adjusted odds ratiosa (95% CI) | Wald Chi-square p-value | |
| First dose | ||||||
| Type of vaccine | ||||||
| Pfizer1 | 43.4% | 71.1% | 20.0% | 34.4% | 1.00 | |
| AstraZeneca2 | 18.6% | 8.6% | 36.5% | 37.6% | 2.53 (2.16, 2.96) | 0.00001 |
| Cansino3 | 15.5% | 7.4% | 26.5% | 14.2% | 1.18 (0.99, 1.42) | 0.072 |
| SinoVac4 | 13.8% | 8.6% | 7.6% | 4.4% | 0.52 (0.41, 0.66) | 0.00001 |
| Sputnik V5 | 4.2% | 1.4% | 4.9% | 6.1% | 2.41 (1.76, 3.29) | 0.00001 |
| J & J6 | 2.9% | 0.2% | 4.3% | 2.3% | 1.27 (0.85, 1.91) | 0.246 |
| Moderna7 | 1.6% | 2.7% | 0.3% | 1.0% | 0.82 (0.49, 1.38) | 0.465 |
| Female sex | 73.5% | 78.6% | 77.8% | 82.9% | 1.45 (1.25, 1.68) | 0.00001 |
| Age < 50 years | 70.8% | 77.9% | 78.6% | 88.1% | 2.29 (1.95, 2.69) | 0.00001 |
| Comorbidity (any) | 19.7% | 21.0% | 16.5% | 19.3% | 1.19 (1.01, 1.41) | 0.033 |
| Allergies | 23.0% | 27.8% | 27.6% | 35.5% | 1.58 (1.37, 1.81) | 0.00001 |
| Smoking | 13.8% | 12.4% | 11.1% | 13.2% | 1.04 (0.87, 1.26) | 0.645 |
| Second dose | ||||||
| Type of vaccine | ||||||
| Pfizer1 | 58.5% | 76.6% | 68.2% | 75.4% | 1.00 | |
| AstraZeneca2 | 24.1% | 11.7% | 20.4% | 10.3% | 0.46 (0.36, 0.58) | 0.0001 |
| SinoVac4 | 12.6% | 8.8% | 6.5% | 5.6% | 0.47 (0.35, 0.63) | 0.0001 |
| Sputnik V5 | 3.9% | 1.5% | 2.0% | 4.3% | 1.29 (0.80, 2.08) | 0.294 |
| Moderna7 | 0.8% | 1.5% | 3.0% | 4.4% | 2.88 (1.59, 5.21) | 0.0001 |
| Female sex | 76.9% | 79.9% | 79.8% | 83.4% | 1.27 (1.03, 1.57) | 0.025 |
| Age <50 years | 57.7% | 73.7% | 63.1% | 79.6% | 2.03 (1.68, 2.45) | 0.0001 |
| Comorbidity (any) | 25.2% | 27.0% | 26.1% | 22.1% | 1.04 (0.85, 1.26) | 0.349 |
| Allergies | 26.0% | 29.9% | 35.0% | 33.1% | 1.2 (1.00, 1.44) | 0.728 |
| Smoking | 14.1% | 11.3% | 10.3% | 14.5% | 1.13 (0.88, 1.44) | 0.046 |
Multivariate ordinal regression analyses of factors associated to an extension of side effects in Mexican population, August to September 2021.
Adjusted by the preventive use of medication to prevent symptoms before vaccination and history of confirmed COVID-19 infection.
BNT162b2 (Pfizer-BioNTech).
ChAdOx1 (AstraZeneca).
mRNA-1273 (Moderna).
CoronaVac (Sinovac Life Sciences).
Gam-COVID-Vac (Gamaleya's Sputnik V).
Ad5-nCoV (CanSinoBIO).
Ad26.CoV2.S (Johnson & Johnson/Janssen).
Factors Associated to Severity of Side Effects
At dose 1, four vaccines were associated to greater severity: ChAdOx1 (AstraZeneca), Ad5-nCoV (CanSinoBIO), Gam-COVID-Vac (Gamaleya's Sputnik V), and Ad26.CoV2.S (Johnson & Johnson/Janssen). Female sex, age <50 years, comorbidity, and allergies were also associated factors, independent of smoking, pre-vaccination medication to prevent symptoms, and history of confirmed COVID-19 infection (Table 6). At dose 2, mRNA-1273 (Moderna) tripled the possibilities of feeling worse compared to the first dose (95% CI 1.82, 5.43; p < 0.0001). In contrast, ChAdOx1 (AstraZeneca) (adjusted OR 0.34, 95% CI 0.26, 0.42; p < 0.0001) and Gam-COVID-Vac (Gamaleya's Sputnik V) (adjusted OR 0.59, 95% CI 0.37, 0.94; p = 0.025) reduced them.
Table 6
| Severity | ||||||
|---|---|---|---|---|---|---|
| Absent | Mild | Moderate | Severe | Adjusted odds ratiosa (95% CI) | Wald Chi-square p-value | |
| First dose | ||||||
| Type of vaccine | ||||||
| Pfizer1 | 49.5% | 41.1% | 16.6% | 26.1% | 1.00 | |
| AstraZeneca2 | 16.5% | 32.8% | 52.7% | 41.6% | 4.32 (3.73, 5.0) | 0.0001 |
| Cansino3 | 15.3% | 11.4% | 17.0% | 23.0% | 1.96 (1.63, 2.36) | 0.0001 |
| SinoVac4 | 11.2% | 4.1% | 3.9% | 5.0% | 0.71 (0.54, 0.93) | 0.013 |
| Sputnik V5 | 4.0% | 5.3% | 7.3% | 3.1% | 3.00 (2.28, 3.94) | 0.0001 |
| J & J6 | 2.3% | 3.3% | 1.9% | 0.6% | 1.68 (1.15, 2.46) | 0.008 |
| Moderna7 | 1.3% | 2.0% | 0.6% | 0.6% | 1.43 (0.86, 2.38) | 0.163 |
| Female sex | 75.4% | 83.3% | 83.3% | 85.7% | 1.52 (1.30, 1.78) | 0.0001 |
| Age < 50 years | 77.2% | 83.9% | 88.9% | 85.7% | 1.58 (1.30, 1.87) | 0.0001 |
| Comorbidity (any) | 18.8% | 19.9% | 18.9% | 23.6% | 1.22 (1.05, 1.43) | 0.011 |
| Allergies | 25.7% | 33.6% | 37.3% | 39.1% | 1.49 (1.31, 1.70) | 0.0001 |
| Smoking | 12.5% | 13.5% | 13.6% | 13.7% | 1.11 (0.93, 1.33) | 0.233 |
Multivariate ordinal regression analyses of factors associated to the severity of side effects in Mexican population, August to September 2021.
Adjusted by the preventive use of medication to prevent symptoms before vaccination and history of confirmed COVID-19 infection.
BNT162b2 (Pfizer-BioNTech).
ChAdOx1 (AstraZeneca).
mRNA-1273 (Moderna).
CoronaVac (Sinovac Life Sciences).
Gam-COVID-Vac (Gamaleya's Sputnik V).
Ad5-nCoV (CanSinoBIO).
Ad26.CoV2.S (Johnson & Johnson/Janssen).
Discussion
In the present study, we analyzed and explored associated factors to adverse reactions after COVID-19 vaccination from different laboratories and schemes (2 single-dose and 5 double-dose vaccines) in the Mexican population characterized by being in their 30s, being a woman, and with high schooling.
Prevalence of at least one side effect after the first dose varied between vaccines. CoronaVac (Sinovac Life Sciences) registered the lowest frequency (55%), which was higher than phases 2 and 3 clinical trials reports with values between 19 and 33% (31, 32). The next vaccine with less adverse effects was mRNA-1273 (Moderna) (69%), lower than 84% documented in a phase 3 clinical trial (33). Three vaccines showed prevalence around 70%, BNT162b2 (Pfizer-BioNTech; 73%), Ad5-nCoV (CanSinoBIO; 75%), and Ad26.CoV2.S (Johnson & Johnson/Janssen; 71%). The BNT162b2 (Pfizer-BioNTech) statistics of side effects are contrasting. An ongoing multinational placebo-controlled clinical trial reported 27% (34), but surveys with self-reported symptoms showed figures between 80 and 92% (21, 22, 35). Ad5-nCoV (CanSinoBIO) and Ad26.CoV2.S (Johnson & Johnson/Janssen) frequencies were close to the ones reported in phase 2 clinical trials. Zhu et al. (36) found 72–74% with Ad5-nCoV (CanSinoBIO) and Sadoff et al. (37) identified 62–63% with low Ad26.CoV2.S (Johnson & Johnson/Janssen) dose and 78–82% with high dose. The vaccines with the highest frequency of side effects were ChAdOx1 (AstraZeneca) and Gam-COVID-Vac (Gamaleya's Sputnik V) (85 and 80%, respectively). Both were within the range of self-report surveys. The former has shown prevalence ranging from 51 to 96% (21, 27, 35, 38, 39) and the second one, prevalence ranging from 71 to 82% (40, 41).
First vs. Second Doses
We found a stronger reaction to the first than the second dose. ChAdOx1 (AstraZeneca) presented the highest difference with +40%, Gam-COVID-Vac (Gamaleya's Sputnik V) with +22%, and CoronaVac (Sinovac Life Sciences) with +10%. The stronger reaction to ChAdOx1 (AstraZeneca) first dose was in line with other reports (14, 42). Jarynowski et al. (20) also showed a higher average of adverse effects with the first than the second dose Gam-COVID-Vac (Gamaleya's Sputnik V) (2.2 ± 1.8 vs. 1.9 ± 1.7). They attributed such a result to the vaccine vector used in dose 2, which is different from dose 1. BNT162b2 (Pfizer-BioNTech) registered an overall difference of +6 indicating higher side effects with dose 1, unlike other studies that had reported more effects with the second dose (15, 18, 19). The discrepancy may be due to differences in age, sex, comorbidities, and history of COVID-19 infection. In addition, to geographic region and immune response variations. A systematic review and meta-analysis conducted by Choe et al. (43) showed that the geographic region was an important source of variation in the immune response to pneumococcal conjugate vaccines. Further research is needed to identify the reasons for an observed result contrary to what was expected. mRNA-1273 (Moderna) was the only vaccine with higher side effects at dose 2, which was in accordance with what the Centers for Disease Control and Prevention (CDC) reports. That is mRNA-1273 (Moderna) tends to present higher symptomatology the second time (16).
Extension of Side Effects
Unlike other studies, this one distinguished the frequency of local and systemic symptoms in a single or combined presentation. At dose 1, very few had local or systemic symptoms in solitary instead they experienced both, which was considered of greater extension. ChAdOx1 (AstraZeneca) and Gam-COVID-Vac (Gamaleya's Sputnik V) were associated to greater extension while CoronaVac (Sinovac Life Sciences) to lesser extension, independent of sex, age, and other potential confounders. At dose 2, the absence of symptoms equaled the category of a combination of local and systemic symptoms and mRNA-1273 (Moderna) was the only vaccine associated with the greater extension. Regarding local symptoms, we identified important differences with the literature. For example, BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (AstraZeneca) each registered 50% of participants with pain at the injection site in dose 1, which was less than that reported before between 68 and 81.2% (18, 21). At dose 2, the rates were 34.5 and 18%, respectively. Moreover, lower than in other studies >70% (18, 44). The rates of fatigue and muscle pain secondary to CoronaVac (Sinovac Life Sciences) in dose 1 were lower than those identified by Djanas et al. (45) (13% vs. 35.8% and 39.6%, respectively). Moreover, in dose 2, BNT162b2 (Pfizer-BioNTech) registered half the frequency reported elsewhere (18, 44). These differences remind the importance of estimating the prevalence of adverse effects in different populations. On the other hand, ChAdOx1 (AstraZeneca) registered higher systemic side effects than BNT162b2 (Pfizer-BioNTech) in dose 1, which was not surprising as this has been pointed out by other authors (18, 21).
The Severity of Side Effects
The severity of side effects varied by the type of vaccine and the number of doses. Four vaccines increased the possibilities of greater severity at the first dose, ChAdOx1 (AstraZeneca), Ad5-nCoV (CanSinoBIO), Gam-COVID-Vac (Gamaleya's Sputnik V), and Ad26.CoV2.S (Johnson & Johnson/Janssen), as compared to BNT162b2 (Pfizer-BioNTech), independent of sex, age, and other potential confounders. There were more respondents suspending activities/missing work and taking medicine for relieving symptoms with ChAdOx1 (AstraZeneca). Kim et al. (18) also reported ChAdOx1 (AstraZeneca) with a higher impact on work productivity (work performance was impaired, took vacation or holiday, missed work). We found more participants seeking medical attention with Ad5-nCoV (CanSinoBIO) followed by ChAdOx1 (AstraZeneca). Kim et al. (18) also identified the latter vaccine with a higher frequency of subsequent need for going to a doctor, an emergency room, or being hospitalized.
Associated Factors
Age, sex, and allergies were associated with greater extension and severity of side effects regardless of the type of vaccine and number of doses. Age <50 years presented the greatest risk, which doubled the chances of having local combined with systemic symptoms. Studies from different regions and different vaccines have documented respondents under 50 years with a higher risk of side effects (18, 20, 22, 27). It has been attributed to a decline in the function of the immune system with age. Women have a higher risk of adverse effects too (18–22). The disparity has been explained by differences in the immune response between men and women (46, 47). We also identified a history of allergies associated to greater extension and severity of side effects. Jahan et al. (27) found 45.1% of their participants had a history of allergic reactions to various allergens, which were associated with sneezing, coughing, itching, swelling, runny nose, and shortness of breath following the first application of ChAdOx1 (AstraZeneca). It appeared that the relative incidence of allergic reactions following administration of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines had been higher for recipients with a prior history of allergies and/or anaphylaxis, respectively (48).
Limitations
Differences in the use of certain vaccines were consistent with the vaccination program in the country, which in turn was a function of vaccines availability. The distribution by age, sex, and schooling was not as heterogeneous as would have been desired; and there was a bias toward young age, female sex, and higher schooling. Some reasons may help to explain it. In Mexico, there are more women than men (51 vs. 49%) and people between 15 and 49 years make up more than half of the population according to the 2020 population census (49). Women tend to participate more in health surveys. The higher presence of young adults reflects their greater familiarity and use of social media compared to older adults. Other authors have also reported more women and young respondents (18–21); and a higher frequency of university or post-university participants in online surveys (19, 27). The combination of higher education and a job with the Ad5-nCoV (CanSinoBIO) can be explained by the fact that this vaccine was applied mainly to schoolteachers and university professors. Additionally, diabetes and hypertension were half the frequency reported in the 2021 National Health and Nutrition Survey (50), probably secondary to the low presence of older adults. These were the ones with the least participation, which agrees with the percentage distribution of population 60 and over that according to the census ranks second least in the country, after that of 50–59 years (12 and 10%, respectively) (49). Future research requires the inclusion of a greater number of men, older adults, and less educated individuals. The study relied on self-report and symptoms were not verified. Some respondents may have incorrectly blamed the vaccine for the experienced side effect. Moreover, those who experienced side effects might have been more interested in participating than those who did not; and rates might be overestimated. Results might have been affected by memory bias. The use of mobile devices for reporting side effects in real-time might produce more accurate rates. Finally, the study focused on the short-term side effects; more research is needed for long-term effects.
Conclusions
Prevalence and degree of adverse reactions differed by the number of doses and type of vaccine. At dose 1, ChAdOx1 (AstraZeneca) was the vaccine with the highest rate of at least one side effect followed by Gam-COVID-Vac (Gamaleya's Sputnik V). Both were associated with greater extension and severity of side effects. ChAdOx1 (AstraZeneca) was the vaccine in which more participants were required to suspend everyday duties or had to miss work. Young age (<50 years), female sex, comorbidity, and history of allergies were associated with greater extension and severity of side effects after the first vaccination, regardless of the type of vaccine and potential confounders. At dose 2, mRNA-1273 (Moderna) was the vaccine with the highest rate of side effects and the only vaccine associated with greater extension and severity of symptoms. Female sex and age under 50 increased the odds of greater extension after the second vaccination. Therefore, after receiving the COVID-19 vaccination, recipients should be advised about potential vaccine symptoms according to the number of doses, the type of vaccine, sex, age, and history of allergies. An informed public will know what to expect, what to do, when and where to seek additional guidance if necessary. Furthermore, measures for preventing or eliminating the unwanted effect might be planned. Continuous studies are necessary to acknowledge more about the post-vaccine symptoms in different populations.
Institutional Review Board Statement
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of the Mexican Social Security Institute (protocol 2021-1909-106, August 9, 2021).
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving human participants were reviewed and approved by Local Committee of Health Research No. 1909, Mexican Social Security Institute. The patients/participants provided their written informed consent to participate in this study.
Author contributions
MC and AS conceptualized the study and contributed to methodology, software, and writing—original draft preparation. BT and AS validated the data. MC, BT, and AS contributed to formal analysis. MC investigated the study. MC, AS, and JG contributed to data curation. MB, GN, JG, and BT contributed to writing, reviewing, and editing. AS and MB contributed to supervision. All authors have read and agreed to the published version of the manuscript.
Acknowledgments
The authors thank to Universidad de Monterrey for the APC funding.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.834744/full#supplementary-material
References
1.
PlattoSWangYZhouJCarafoliE. History of the COVID-19 pandemic: origin, explosion, worldwide spreading. Biochem Biophys Res Commun. (2021) 538:14–23. 10.1016/j.bbrc.2020.10.087
2.
ZhouPYangX-LWangX-GHuBZhangLZhangWet al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. (2020) 579:270–3. 10.1038/s41586-020-2012-7
3.
DeslandesABertiVTandjaoui-LambotteYAllouiCCarbonnelleEZaharJRet al. SARS-CoV-2 was already spreading in France in late December 2019. Int J Antimicrob Agents. (2020) 55:106006. 10.1016/j.ijantimicag.2020.106006
4.
RobertsDLRossmanJSJarićI. Dating first cases of COVID-19. LeeB, editor. PLoS Pathog. (2021) 17:e1009620. 10.1371/journal.ppat.1009620
5.
JacksonLAAndersonEJRouphaelNGRobertsPCMakheneMColerRNet al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. (2020) 383:1920–31. 10.1056/NEJMoa2022483
6.
CallawayE. Russia announces positive COVID-vaccine results from controversial trial. Nature. (2020). 10.1038/d41586-020-03209-0
7.
National Guiding Policy for Vaccination Against SARS-CoV-2 for the Prevention of COVID-19 in Mexico. Guiding document (2021). Available online at: https://coronavirus.gob.mx/wp-content/uploads/2021/01/PolVx_COVID_-11Ene2021.pdf (accessed January 25, 2022).
8.
CarnallaMBasto-AbreuASternDBautista-ArredondoSShamah-LevyTAlpuche-ArandaCMet al. Acceptance, refusal and hesitancy of Covid-19 vaccination in Mexico: Ensanut 2020 Covid-19. Salud Publica Mex. (2021) 63:598–606. 10.21149/12696
9.
WoutersOJShadlenKCSalcher-KonradMPollardAJLarsonHJTeerawattananonYet al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. (2021) 397:1023–34. 10.1016/S0140-6736(21)00306-8
10.
Our world in data. Coronavirus (COVID-19) Vaccinations. Available online at: https://ourworldindata.org/covid-vaccinations?country=OWID_WRL (accessed Feb 2, 2022).
11.
Mexico - COVID-19 - Vaccines administered. Available online at: https://datosmacro.expansion.com/otros/coronavirus-vacuna/mexico (accessedFeb 2, 2022).
12.
Andrzejczak-GrzadkoSCzudyZDonderskaM. Side effects after COVID-19 vaccinations among residents of Poland. Eur Rev Med Pharmacol Sci. (2021) 25:4418–21. 10.26355/eurrev_202106_26153
13.
KleinNPLewisNGoddardKFiremanBZerboOHansonKEet al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. (2021) 326:1390. 10.1001/jama.2021.15072
14.
United Kingdom Goverment,. Coronavirus Vaccine - Weekly Summary of Yellow Card Reporting. (2021). Available online at: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting (acceesed Nov 13, 2021).
15.
Centers for Disease Control Prevention. Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events. (2021). Available online at: https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html (accessed December 14, 2021).
16.
Centers for Disease Control Prevention. The Moderna COVID-19 Vaccine's Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events. (2021). Available online at: https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/reactogenicity.html
17.
Centers for Disease Control Prevention. The Janssen COVID-19 Vaccine's Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events. (2021). Available online at: https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/reactogenicity.html (accessed December 14, 2021).
18.
KimTParkSYYuSParkJWLeeEJeonMHet al. Impacts of side effects to BNT162b2 and the first dose of ChAdOx1 Anti-SARS-CoV-2 vaccination on work productivity, the need for medical attention, and vaccine acceptance: a multicenter survey on healthcare workers in referral teaching hospitals in the Re. Vaccines. (2021) 9:648. 10.3390/vaccines9060648
19.
El-ShitanyNAHarakehSBadr-EldinSMBagherAMEidBGAlmukadiHSet al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among saudi residents: a retrospective cross-sectional study. Int J Gen Med. (2021) 14:1389–401. 10.2147/IJGM.S310497
20.
JarynowskiASemenovAKamińskiMBelikV. Mild adverse events of Sputnik V vaccine in Russia: social media content analysis of telegram via deep learning. J Med Internet Res. (2021) 23:1–14. 10.2196/preprints.30529
21.
BaeSLeeYWLimSYLeeJ-HLimJSLeeSet al. Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea. J Korean Med Sci. (2021) 36:e115. 10.3346/jkms.2021.36.e115
22.
RiadAHockováBKantorováLSlávikRSpurnáLStebelAet al. Side effects of mRNA-based COVID-19 vaccine: nationwide phase IV study among healthcare workers in Slovakia. Pharmaceuticals. (2021) 14:873. 10.3390/ph14090873
23.
TissotNBrunelA-SBozonFRosolenBChirouzeCBouillerK. Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine. Vaccine. (2021) 39:5087–90. 10.1016/j.vaccine.2021.07.047
24.
MathioudakisAGGhrewMUstianowskiAAhmadSBorrowRPapavasileiouLPet al. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey. Life. (2021) 11:249. 10.3390/life11030249
25.
Ministry of Health. Adverse Effects When Being Vaccinated Against Covid-19. Available online at: http://vacunacovid.gob.mx/wordpress/eventos-adversos/ (accessed January 28, 2022).
26.
KlugarMRiadAMekhemarMConradJBuchbenderMHowaldtH-Pet al. Side effects of mRNA-based and viral vector-based COVID-19 vaccines among german healthcare workers. Biology. (2021) 10:752. 10.3390/biology10080752
27.
JahanNRahmanFISahaPEtherSARoknuzzamanASarkerRet al. Side effects following administration of the first dose of Oxford-AstraZeneca's covishield vaccine in Bangladesh: a cross-sectional study. Infect Dis Rep. (2021) 13:888–901. 10.3390/idr13040080
28.
Centers for Disease Control and Prevention (CDC). Epi Info. Atlanta, GA (2020).
29.
World Medical Association Declaration of Helsinki. JAMA. (2013) 310:2191. 10.1001/jama.2013.281053
30.
HarrisCVBradlynASCoffmanJGunelECottrellL. BMI-based body size guides for women and men: development and validation of a novel pictorial method to assess weight-related concepts. Int J Obes. (2008) 32:336–42. 10.1038/sj.ijo.0803704
31.
TanrioverMDDoganayHLAkovaMGünerHRAzapAAkhanSet al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. (2021) 398:213–22. 10.1016/S0140-6736(21)01429-X
32.
ZhangYZengGPanHLiCHuYChuKet al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. (2021) 21:181–92. 10.1016/S1473-3099(20)30843-4
33.
BadenLREl SahlyHMEssinkBKotloffKFreySNovakRet al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. (2021) 384:403–16. 10.1056/NEJMoa2035389
34.
PolackFPThomasSJKitchinNAbsalonJGurtmanALockhartSet al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. (2020) 383:2603–15. 10.1056/NEJMoa2034577
35.
AlghamdiANAlotaibiMIAlqahtaniASAl AboudDAbdel-MoneimAS. BNT162b2 and ChAdOx1 SARS-CoV-2 post-vaccination side-effects among Saudi vaccinees. Front Med. (2021) 8:760047. 10.3389/fmed.2021.760047
36.
ZhuF-CGuanX-HLiY-HHuangJ-YJiangTHouL-Het al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. (2020) 396:479–88. 10.1016/S0140-6736(20)31605-6
37.
SadoffJGrayGVandeboschACárdenasVShukarevGGrinsztejnBet al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. (2021) 384:2187–201. 10.1056/NEJMoa2101544
38.
SultanaAShahriarSTahsinMRMimSRFatemaKRSahaAet al. A retrospective cross-sectional study assessing self-reported adverse events following immunization (AEFI) of the COVID-19 vaccine in Bangladesh. Vaccines. (2021) 9:1090. 10.3390/vaccines9101090
39.
AlhazmiAAlamerEDawsDHakamiMDarrajMAbdelwahabSet al. Evaluation of side effects associated with COVID-19 vaccines in Saudi Arabia. Vaccines. (2021) 9:674. 10.3390/vaccines9060674
40.
PagottoVFerloniAMercedes SorianoMDíazMBraguinsky GoldeNGonzálezMIet al. Active monitoring of early safety of Sputnik V vaccine in Buenos Aires, Argentina. Medicina. (2021) 81:408–14.
41.
ZareHRezapourHMahmoodzadehSFereidouniM. Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran. Int Immunopharmacol. (2021) 101:108351. 10.1016/j.intimp.2021.108351
42.
European Medicines Agency,. Vaxzevria (previously COVID-19 Vaccine AstraZeneca): EPAR - Product information (updated). (2021). Available online at: https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf (accessed November 13, 2021).
43.
ChoeYJBlattDBLeeHJChoiEH. Associations between geographic region and immune response variations to pneumococcal conjugate vaccines in clinical trials: a systematic review and meta-analysis. Int J Infect Dis. (2020) 92:261–8. 10.1016/j.ijid.2019.12.021
44.
ShimabukuroT. Vaccine Safety Update. Advisory Committee on Imunization Practices (ACIP) (2021). Available online at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-01/06-COVID-Shimabukuro.pdf (accessed Nov 13, 2021).
45.
DjanasDYusirwan MartiniRDRahmadian PutraHZanirAet al. Survey data of COVID-19 vaccine side effects among hospital staff in a national referral hospital in Indonesia. Data Br. (2021) 36:107098. 10.1016/j.dib.2021.107098
46.
JacobsenHKleinSL. Sex differences in immunity to viral infections. Front Immunol. (2021) 12:720952. 10.3389/fimmu.2021.720952
47.
KleinSLJedlickaAPekoszA. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. (2010) 10:338–49. 10.1016/S1473-3099(10)70049-9
48.
DesaiAPDesaiAPLoomisGJ. Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration. Vaccine. (2021) 39:4407–9. 10.1016/j.vaccine.2021.06.058
49.
National National Institute of Statistics Geography Informatics (INEGI). Population and Housing Census. (2020). Available online at: https://www.inegi.org.mx/programas/ccpv/2020/default.html#Tabulados (accessed February 3, 2022).
50.
Shamah-LevyTRomero-MartínezMBarrientos-GutiérrezTCuevas-NasuLBautista-ArredondoSColcheroMAet al. National Health and Nutrition Survey 2020 on Covid-19. National results. Cuernavaca, México (2021).
Summary
Keywords
COVID-19, SARS-CoV-2, side effects, local effects, systemic effects, vaccination, vaccine
Citation
Camacho Moll ME, Salinas Martínez AM, Tovar Cisneros B, García Onofre JI, Navarrete Floriano G and Bermúdez de León M (2022) Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population. Front. Public Health 10:834744. doi: 10.3389/fpubh.2022.834744
Received
13 December 2021
Accepted
07 February 2022
Published
14 March 2022
Volume
10 - 2022
Edited by
Abanoub Riad, Masaryk University, Czechia
Reviewed by
Shyh Poh Teo, Raja Isteri Pengiran Anak Saleha Hospital, Brunei; Andrea Pokorná, Masaryk University, Czechia; Carlos Miguel Rios-González, National University of Caaguazú, Paraguay; Arkadiusz Dziedzic, Medical University of Silesia, Poland; Ahmad Sofi-Mahmudi, National Institute for Medical Research and Development, Iran
Updates
Copyright
© 2022 Camacho Moll, Salinas Martínez, Tovar Cisneros, García Onofre, Navarrete Floriano and Bermúdez de León.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: María Elena Camacho Moll mvz_elenacamacho@hotmail.comAna María Salinas Martínez amsalinasmartinez@gmail.com
This article was submitted to Family Medicine and Primary Care, a section of the journal Frontiers in Public Health
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.